ADC Therapeutics SA logo
ADC Therapeutics SA ADCT
$ 3.94 -0.51%

Annual report 2022
added 12-21-2024

report update icon

ADC Therapeutics SA Deferred Revenue 2011-2026 | ADCT

Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.
Features of the metric
  • Sources of future cash inflows
    A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability.
  • Assessment of operational stability
    Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages.
  • Risks and obligations
    Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results.
  • Analysis of liquidity and cash flow
    Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks.
  • Impact on company valuation
    In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).

Annual Deferred Revenue ADC Therapeutics SA

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - 834 K 1.76 M 2.32 M 1.84 M - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
2.32 M 834 K 1.69 M

Deferred Revenue of other stocks in the Biotechnology industry

Issuer Deferred Revenue Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
86.5 M - 2.43 % $ 254 M germanyGermany
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
517 K - - $ 1.01 B usaUSA
I-Mab I-Mab
IMAB
563 K - - $ 866 M chinaChina
Midatech Pharma plc Midatech Pharma plc
MTP
1.3 M - -18.52 % $ 27.3 M britainBritain
AIkido Pharma AIkido Pharma
AIKI
957 K - 1.93 % $ 17.4 M usaUSA
Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation
NYMX
2.51 M - -19.68 % $ 18.4 M canadaCanada
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
15.9 M - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
124 K - 2.54 % $ 160 B franceFrance
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
2.64 M $ 21.96 -0.68 % $ 3.64 B usaUSA
RedHill Biopharma Ltd. RedHill Biopharma Ltd.
RDHL
19.5 M $ 1.02 -0.49 % $ 428 M israelIsrael
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
2.69 M - -1.52 % $ 24.7 M usaUSA
Advaxis Advaxis
ADXS
165 K - -9.65 % $ 45.9 M usaUSA
AlloVir AlloVir
ALVR
2.66 M - 4.14 % $ 49.1 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
85.7 K - -11.43 % $ 502 K usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
151 K $ 6.4 4.4 % $ 63.3 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
667 K - - $ 8.42 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
20.2 M - 17.91 % $ 11.1 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
643 K $ 21.41 1.9 % $ 1 B usaUSA
Aravive Aravive
ARAV
4.41 M - -13.39 % $ 1.45 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
1.72 M - -4.8 % $ 255 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
2.19 M - 5.93 % $ 314 M canadaCanada
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
2.62 M - -2.5 % $ 5.88 M usaUSA
Kazia Therapeutics Limited Kazia Therapeutics Limited
KZIA
138 K $ 12.26 3.72 % $ 1.62 B australiaAustralia
AgeX Therapeutics AgeX Therapeutics
AGE
283 K - -10.17 % $ 12.2 K usaUSA
BioNTech SE BioNTech SE
BNTX
300 M $ 105.46 -0.09 % $ 27.2 B germanyGermany
BeiGene, Ltd. BeiGene, Ltd.
BGNE
187 M - 0.49 % $ 251 B cayman-islandsCayman-islands
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
6.3 M - - $ 26.5 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
1.09 M $ 4.08 0.25 % $ 436 M usaUSA
Cara Therapeutics Cara Therapeutics
CARA
22.3 M - -3.03 % $ 260 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
2.35 M - - $ 35.4 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
405 K $ 2.91 -1.36 % $ 4.79 M israelIsrael
bluebird bio bluebird bio
BLUE
2.28 M - - $ 546 M usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
1.69 M - - $ 3.45 B usaUSA